The novel regimen of tremelimumab in combination with durvalumab provides a favorable safety profile and clinical activity for patients with advanced hepatocellular carcinoma

Autores: Kelley, R. ; Kudo, M. ; Harris, W.; Ikeda, M. ; Okusaka, T. ; Kang, Y. ; Qin, S. ; Tai, D. ; Lim, H. ; Yau, T.; Yong, W.; Cheng, A.; Gasbarrini, A.; de Braud, F.; Bruix, J. ; Borad, M.; Standifer, N.; He, P. ; Negro, A.; Vlahovic, G. ; Sangro Gómez-Acebo, Bruno Carlos; Abou-Alfa, G.